STAT+: Trump Is Getting More Credit than Biden for Efforts to Lower Drug Prices

Why It Matters

Public perception drives political capital for drug‑price reforms and can influence future legislative agendas, affecting both patients and the pharmaceutical market.

Key Takeaways

• 41% expect Trump to cut drug prices
• 79% Republicans, 11% Democrats share that view
• Only 31% aware of Medicare negotiation program
• Public credit exceeds awareness of Biden's legislation
• Perception may shape future drug pricing reforms

Pulse Analysis

The KFF poll highlights how partisan lenses shape Americans’ views on drug‑price policy. While 41% of respondents credit the Trump administration with lowering costs, the split is stark: Republicans overwhelmingly attribute price‑reduction potential to Trump, whereas Democrats largely dismiss it. This divergence reflects broader political narratives rather than a detailed assessment of policy outcomes, underscoring the challenge of communicating complex health‑care reforms to a polarized electorate.

Under the Trump administration, a series of executive actions—such as the 2022 price‑transparency rule and efforts to promote generic competition—were marketed as aggressive steps to curb high drug prices. In contrast, the Biden administration’s signature achievement, the Medicare drug‑price negotiation provision embedded in the Inflation Reduction Act, remains less visible to the public, with only 31% awareness in the poll. The legislative approach targets high‑cost specialty drugs directly through negotiated pricing, a fundamentally different mechanism from Trump’s market‑based tactics.

The perception gap has tangible implications for future policy. If voters continue to associate price‑lowering successes with partisan branding, bipartisan support for comprehensive reforms may stall, limiting the scope of negotiations and transparency measures. Pharmaceutical firms, meanwhile, must navigate an environment where public sentiment can sway regulatory pressure. Enhancing public education about the mechanics and benefits of Medicare negotiations could bridge the awareness divide, fostering a more informed dialogue that aligns political incentives with tangible cost‑saving outcomes for patients.